Oxandrolone metabolites: how the body breaks down the drug
Oxandrolone is an unusual oral steroid: it is remarkably resistant to metabolism and is excreted largely unchanged, which makes its breakdown an instructive case study. This editorial overview explains how the body handles oxandrolone, which metabolites it forms, and why these facts matter for both liver health and anti-doping science.
What oxandrolone is
Oxandrolone is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone. Structurally it is distinctive: an oxygen atom replaces a carbon in the steroid A-ring, and it carries the 17-alpha-methyl group that makes oral steroids active by mouth. These features give it a particular pharmacological personality, including its famed metabolic stability.
Medically, oxandrolone has legitimate but narrow uses. It has been used to help restore weight after severe burns, trauma, surgery or illness, and in certain wasting conditions. In the UK it is a prescription-only and controlled substance; it is not a general tonic, and its medical use is confined to specific, supervised indications.
Oxandrolone acquired a reputation as a "mild" steroid, partly because of its relatively favourable androgenic profile at therapeutic doses. That reputation, however, should not be mistaken for an absence of risk; like all 17-alkylated oral steroids it places demands on the liver and alters cholesterol, as discussed below.
This article is concerned with metabolism — the biological fate of the molecule — not with how it might be used. It explains why oxandrolone behaves so differently from most steroids once it is inside the body.
An unusually stable molecule
The defining feature of oxandrolone's pharmacology is its resistance to metabolism. Where most steroids are extensively transformed by the liver into many metabolites, oxandrolone is metabolised relatively little. The combination of the 17-alpha-methyl group and the oxygen-containing A-ring makes the molecule chemically stable and hard for the usual enzymes to break down.
This stability has two consequences. First, a large proportion of a dose is excreted intact rather than as transformed metabolites — unusual among steroids. Second, the drug has a relatively short plasma half-life compared with injectable esters but behaves predictably because it is not heavily processed.
What metabolism does occur produces a small number of characteristic products, discussed in the next section. The point to grasp is that oxandrolone bucks the usual pattern: most of its elimination does not depend on extensive chemical transformation.
This resistance to breakdown is not merely a curiosity. It helps explain the drug's consistent pharmacology and, as anti-doping chemists discovered, its detectability — because the unchanged drug and its few metabolites can be measured reliably in urine.
Excretion and the kidney
Because oxandrolone is not heavily metabolised, the kidneys play a larger-than-usual role in clearing it. A substantial fraction of a dose appears in the urine as the unchanged drug, alongside a smaller contribution from metabolites. This renal route of elimination distinguishes oxandrolone from steroids that are cleared mainly through hepatic transformation.
The practical implication is that kidney function influences how the drug is cleared. In people with impaired renal function, excretion would be expected to be slower, altering the drug's handling. This is one reason any medical use requires assessment of the individual, not a one-size-fits-all approach.
From the anti-doping perspective, renal excretion of the intact drug is helpful: the parent compound itself can be detected in urine. Combined with its characteristic metabolites, this gives laboratories a robust set of markers, and oxandrolone is detectable for a meaningful period after use.
The liver is still involved — it performs the limited metabolism that does occur and handles the 17-alkylated molecule — but the balance between hepatic and renal routes is shifted compared with most oral steroids. This dual pathway is part of what makes oxandrolone a textbook example in steroid pharmacology.
Key metabolites and detection
The metabolism that does occur yields a small set of hydroxylated and reduced products. The most analytically important include epioxandrolone (a C17 epimer) and hydroxylated metabolites such as 17-epioxandrolone and 18-hydroxy derivatives, which anti-doping laboratories use as markers. The parent drug itself is also measured.
| Marker | Nature | Role in testing |
|---|---|---|
| Unchanged oxandrolone | Parent drug in urine | Direct evidence of exposure |
| Epioxandrolone | C17 epimer | Characteristic long-lived marker |
| Hydroxylated metabolites | Phase I products | Extend the detection window |
Research by anti-doping scientists has mapped these metabolites precisely, allowing detection of oxandrolone use for a useful window after the last dose. The epimer, in particular, serves as a stable signature. This work underpins the ability of accredited laboratories to identify the drug even at low concentrations.
Oxandrolone has also appeared as a contaminant in supplements and counterfeit products, so the detection of its metabolites in an athlete's sample can sometimes reflect inadvertent exposure. The analytical signature does not, by itself, distinguish deliberate from accidental intake; that requires further investigation.
For athletes, the message is the familiar one: these substances are detectable, and the stability that makes oxandrolone pharmacologically predictable also makes its markers reliable for testing. Any assumption of a short, easily cleared window is mistaken.
Why this matters for health and testing
The metabolic story connects to health in two ways. First, oxandrolone is a 17-alpha-alkylated oral steroid, and this class is associated with liver strain — raised liver enzymes and, rarely, more serious hepatic effects such as cholestasis or peliosis hepatis. Although oxandrolone is often considered among the less hepatotoxic orals, it is not free of this class risk.
Second, like other anabolic steroids, oxandrolone adversely affects cholesterol, tending to lower the protective HDL fraction. Because it derives from dihydrotestosterone and is not aromatised to oestrogen, its side-effect profile differs from testosterone-based steroids, but the cardiovascular and lipid concerns remain relevant, especially with higher exposure.
The anti-doping dimension reinforces that use carries consequences beyond health. Oxandrolone is prohibited at all times under the World Anti-Doping Code, and its detectable metabolites mean that use can be identified long after any subjective effect has passed. For tested athletes, this is a decisive practical consideration.
Anyone taking a 17-alkylated oral steroid, whether medically or otherwise, should be aware of warning signs of liver stress — jaundice, dark urine, abdominal pain, unusual fatigue — and seek medical assessment if they occur. These are general signals that warrant investigation regardless of the suspected cause.
Conclusions of the editorial team
Oxandrolone is the steroid that refuses to be broken down. Its chemical stability means much of a dose is excreted unchanged, with the kidneys taking a larger role than usual and only a few characteristic metabolites forming. This unusual profile makes it a favourite teaching example in steroid pharmacology.
That same stability makes it reliably detectable, so the idea of a short, easily cleared window is a misconception. And despite its reputation for mildness, it remains a 17-alkylated oral steroid with the attendant liver and cholesterol concerns of its class.
Readers may also find our material on 17-alpha-alkylation and liver load, on how anti-doping laboratories read a urine sample, and on the metabolism of other oral steroids useful for context.
References
- Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001–1020.
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
- Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders. Drugs. 2004;64(7):725–750.
- Massé R, Bi HG, Ayotte C, et al. Studies on anabolic steroids: detection and characterization of oxandrolone metabolites. Biol Mass Spectrom. 1991;20(5):322–330.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- World Anti-Doping Agency. The 2024 Prohibited List, International Standard. Montreal: WADA; 2024.
